Boehringer Ingelheim (BI) has hosted several disease-specific TweetChats focused on atrial fibrillation, chronic obstructive pulmonary disorder (COPD) and lung cancer. Despite the regulatory challenges posed by such activities, these were all successful, both in terms of delivering value to stakeholders and to BI, while remaining compliant with existing laws and regulations.
This article reviews BI's "playbook" -- titled "How pharma TweetChats can drive healthcare innovation" -- which provides detailed insights for planning and delivering successful pharma TweetChats. The authors of the playbook -- Patricia Alves, Social Media Community Manager, and Jaclyn Fonteyne, Social Media Specialist, at BI -- were also interviewed for this article.
Topics include (partial list)
Download the full text PDF file here:
- Sharing Lessons
- Planning a TweetChat
- Moderator or No Moderator?
- Measuring Success
- The Future of Pharma TweetChats